Protagenic Therapeutics
$ 0.42
-5.57%
24 Feb - close price
- Market Cap 867,550 USD
- Current Price $ 0.42
- High / Low $ 0.46 / 0.42
- Stock P/E N/A
- Book Value -2.43
- EPS -13.13
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.90 %
- ROE -5.13 %
- 52 Week High 14.28
- 52 Week Low 0.25
About
Protagenic Therapeutics, Inc., a preclinical biopharmaceutical company, is dedicated to the discovery and development of therapies to treat stress-related mood and neuropsychiatric disorders. The company is headquartered in New York, New York.
Analyst Target Price
$4.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-26 | 2025-08-29 | 2025-05-13 | 2025-03-31 | 2024-11-12 | 2024-08-14 | 2024-05-15 | 2023-11-14 | 2023-08-14 | 2023-05-15 | 2023-03-31 | 2022-11-14 |
| Reported EPS | -0.47 | -1.3664 | -2.7524 | -0.239 | -0.1415 | -0.3616 | -0.3829 | -0.3225 | -0.2793 | -0.1663 | -0.1392 | -0.0535 |
| Estimated EPS | None | None | None | None | None | None | None | None | None | 0 | 0 | 0 |
| Surprise | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.1663 | -0.1392 | -0.0535 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PTIX
2026-01-19 21:58:15
U.S. stocks, including the Dow Jones, S&P 500, and NASDAQ, experienced gains, with DigiAsia Corp surging impressively after announcing a Bitcoin strategy. Globally, European markets were mixed, and Asian markets generally closed lower, while the CB Leading Index showed a 1% decline, raising potential economic concerns. The report also highlights Protagenic Therapeutics shares spiking, contributing to the positive U.S. market performance.
2026-01-09 16:29:21
Protagenic Therapeutics (PTIX) announced it would be delisted from Nasdaq effective January 2, 2026, due to failing to meet listing requirements. The company's securities are expected to begin trading on the over-the-counter market starting January 5, 2026. While Protagenic plans to continue SEC filings and evaluate options for relisting, TipRanks' AI Analyst assigned an "Underperform" rating, citing significant financial difficulties, no revenue, persistent losses, and weak market momentum for the biotechnology company.
2026-01-05 13:08:58
Protagenic Therapeutics (PTIX) received a delisting notice from Nasdaq on December 31, 2025, due to non-compliance with listing requirements for minimum stockholders' equity and timely SEC filings. Trading on Nasdaq ceased after January 2, 2026, and the company's common stock and warrants are anticipated to begin OTC quotation on January 5, 2026. This information is based on an SEC filing from Protagenic Therapeutics.
2026-01-05 13:08:58
Protagenic Therapeutics will commence trading on the OTC market following its delisting from Nasdaq due to failure to meet listing requirements. The company announced its intention to continue filing SEC reports and is exploring options to regain Nasdaq compliance. This move follows recent positive safety results for its drug candidate PT00114 and legal action regarding an acquisition.
2026-01-01 07:09:19
Protagenic Therapeutics, Inc. has received a Nasdaq non-compliance notice due to failing minimum stockholders' equity requirements and delayed filing of its Form 10-Q. The company plans to request a hearing to appeal the determination to delist its securities and present a plan to address the deficiencies.
2025-12-20 16:09:06
Protagenic Therapeutics, Inc. (NASDAQ:PTIX) announced it will present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27, 2022, at 10:30 AM ET. The company, a biopharmaceutical firm, is focused on developing drug product candidates for stress-related neurologic disorders. This presentation offers an opportunity for investors to learn more about the company's pre-clinical efforts in neuro-active peptides.
